相似文献
1
Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches.
Diagnostics (Basel). 2023 Dec 16;13(24):3680. doi: 10.3390/diagnostics13243680.
2
How do we approach the management of medulloblastoma in young children?
Pediatr Blood Cancer. 2022 Oct;69(10):e29838. doi: 10.1002/pbc.29838. Epub 2022 Jun 10.
3
Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
Cancer Med. 2020 Aug;9(16):5807-5818. doi: 10.1002/cam4.3199. Epub 2020 Jun 30.
4
Management of high-risk medulloblastoma.
Neurochirurgie. 2021 Feb;67(1):61-68. doi: 10.1016/j.neuchi.2019.05.007. Epub 2019 Jun 20.
5
A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma.
Front Oncol. 2021 Sep 2;11:744739. doi: 10.3389/fonc.2021.744739. eCollection 2021.
6
Radiotherapy Advances in Paediatric Medulloblastoma Treatment.
Clin Oncol (R Coll Radiol). 2019 Mar;31(3):171-181. doi: 10.1016/j.clon.2019.01.001. Epub 2019 Jan 14.
7
Chemotherapy for children with medulloblastoma.
Cochrane Database Syst Rev. 2015 Jan 1;1(1):CD006678. doi: 10.1002/14651858.CD006678.pub2.
8
Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.
J Clin Oncol. 1999 Jul;17(7):2127-36. doi: 10.1200/JCO.1999.17.7.2127.
9
Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
J Neurooncol. 1999;45(2):135-40. doi: 10.1023/a:1006133404936.
10
Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
Pediatr Blood Cancer. 2020 Nov;67(11):e28572. doi: 10.1002/pbc.28572. Epub 2020 Jul 25.
引用本文的文献
1
Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments.
Brain Sci. 2025 Aug 21;15(8):896. doi: 10.3390/brainsci15080896.
2
Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma.
Diagnostics (Basel). 2024 Feb 7;14(4):358. doi: 10.3390/diagnostics14040358.
本文引用的文献
1
Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia.
Front Oncol. 2023 Oct 18;13:1278611. doi: 10.3389/fonc.2023.1278611. eCollection 2023.
2
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437.
3
Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
Neuro Oncol. 2024 Apr 5;26(4):609-622. doi: 10.1093/neuonc/noad191.
4
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
Clin Cancer Res. 2023 Dec 15;29(24):5031-5037. doi: 10.1158/1078-0432.CCR-23-0348.
5
Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
Neuro Oncol. 2023 Dec 8;25(12):2273-2286. doi: 10.1093/neuonc/noad114.
6
Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.
J Clin Med. 2023 Feb 10;12(4):1415. doi: 10.3390/jcm12041415.
7
Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups.
Neuro Oncol. 2023 Aug 3;25(8):1518-1529. doi: 10.1093/neuonc/noad027.
8
Hypogonadism After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):569-578. doi: 10.1016/j.ijrobp.2023.01.001. Epub 2023 Jan 12.
9
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
J Clin Oncol. 2023 Apr 1;41(10):1921-1932. doi: 10.1200/JCO.21.02968. Epub 2022 Dec 22.
10
Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach.
Cancers (Basel). 2022 Oct 19;14(20):5128. doi: 10.3390/cancers14205128.
Zotero 插件